15 results about "Aciclovir" patented technology

The invention relates to compound herba houttuyniae eye drops as well as a preparation method and application of the compound herba houttuyniae eye drops. Comprising the following preparation raw materials in percentage by mass: 1-6% of a herba houttuyniae extracting solution, 1-5% of an aglaia odorata extracting solution, 1-2% of a gelidium amansii extracting solution, 0.1-0.3% of acyclovir, 0.1-0.3% of tobramycin, 0.01-0.1% of dexamethasone sodium phosphate, 0.1-1% of sodium hyaluronate, 0.1-3% of glycerol and 88-93% of purified water. According to the compound herba houttuyniae eye drops prepared by the preparation method disclosed by the invention, the herba houttuyniae extracting solution, the aglaia odorata extracting solution, the gelidium amansii extracting solution, the acyclovir, the tobramycin and the dexamethasone sodium phosphate are combined for use, so that the compound herba houttuyniae eye drops have a relatively good curative effect on pets suffering from bacterium and virus mixed infection type conjunctivitis / keratitis; the compound herba houttuyniae eye drops are good in high-temperature-resistant storage stability and good in curative effect, the problem of frequent administration can be reduced, and the compound herba houttuyniae eye drops are more convenient to use and store.

The invention relates to the technical field of biological medicines, relates to applications of caerin1.1, caerin1.9 and caerin1.1 / 1.9 in preparation of medicines for preventing / treating viruses, and in particular relates to applications of caerin1.1, caerin1.9 and caerin1.1 / 1.9 in preparation of medicines for preventing / treating herpes simplex viruses. The herpes simplex virus disclosed by the invention is one or two of HSV-1 (Herpes Simplex Virus) or HSV-2 (Herpes Simplex Virus). The caerin1.1, the caerin1.9 or the composition of the caerin1.1 and the caerin1.9 disclosed by the invention has different degrees of prevention and treatment effects on HSV-1 and / or HSV-2, and has a more obvious effect on the HSV-2. Compared with an existing antiviral drug, the compound has a better effect of preventing and treating viruses, the prevention effect is obviously better than that of acyclovir, the application range is wide, and potential toxic and side effects are low.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an antiviral drug acyclovir in preparation of a tumor immunotherapy drug. According to the invention, acyclovir is utilized to induce macrophages to become an M1 phenotype, the phagocytic function and the antigen presentation capability of the macrophages are enhanced, and the maturation of dendritic cells is promoted, so that the anti-tumor effect is realized. In an effective concentration which is non-toxic to a macrophage line RAW264.7, acyclovir significantly promotes phenotype transformation of macrophages to M1, and significantly enhances the cell phagocytic ability and antigen presentation ability of the macrophages. Meanwhile, the acyclovir in an effective concentration can also remarkably promote maturation of bone marrow-derived dendritic cells, so that new application of the acyclovir in the field of tumor immunotherapy is found. According to the method, the application range of acyclovir and immune cell immunotherapy is expanded, and a new feasible clinical treatment scheme is provided for anti-tumor immunotherapy.

The invention relates to the field of antiviral drugs, in particular to application of a miRNA (micro Ribonucleic Acid) simulant in preparation of anti-I-type herpes simplex virus drugs. The miRNA simulant provided by the invention is an analogue of I-type herpes simplex virus coding miR-H5-5p and is double-stranded RNA synthesized by a chemical method, the molecular weight of the miRNA simulant is about 13300 Daltons, and the sequence of the miRNA simulant is shown as SEQ ID NO. 1 or SEQ ID NO. 2. The miRNA simulant disclosed by the invention can show remarkable activity of resisting the acyclovir-resistant I-type herpes simplex virus in HEK293T cells and Vero cells, so that the miRNA simulant can be used for preparing the medicine for resisting the acyclovir-resistant I-type herpes simplex virus.

The present invention relates to the field of pharmaceutical chemistry technology and specifically discloses the use of an alkaloid compound in the preparation of a drug having an anti-herpes simplex virus type II effect. The alkaloid compound has a structure represented by Formula I. Studies have shown that the alkaloid compound having the structure represented by Formula I has highly significant anti-herpes simplex virus type II activity, and its anti-herpes simplex virus type II activity is superior to that of the positive drug acyclovir; therefore, using it as an active ingredient in the preparation of a drug having an anti-herpes simplex virus type II effect has important application value.

The invention provides application of a targeted Hsp90 alpha compound in treatment of infectious encephalitis and improvement of clinical drug resistance, and belongs to the technical field of medicines. The targeted Hsp90 alpha compound disclosed by the invention has a structure as shown in a formula 1, and a parent nucleus structure of the targeted Hsp90 alpha compound is (3, 6, 6-trimethyl-4-oxo-4, 5, 6, 7-tetrahydro-1H-indazole-1-yl) benzamide. The targeted Hsp90 alpha compound can effectively treat infectious encephalitis, can treat infectious encephalitis caused by acyclovir and other nucleoside drug resistance viruses, and improves the clinical drug resistance problem of infectious encephalitis.

Disclosed is a method for treating a condition, which includes the steps of: selecting a patient for treatment who has the condition; administering to the patient at least one active pharmaceutical ingredient (API); and administering to the patient at least one metal complex represented by formula (I):including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof. Also disclosed is a composition for conducting the method, which includes: at least one API selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir; and at least one metal complex effective to potentiate an efficacy of the API to treat the condition, wherein the at least one metal complex is represented by formula (I), including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof.

The present application relates to a kind of sustained-release acyclovir tablets and its preparation process, belong to the technical field of medicine.The acyclovir tablet provided by the present application has immediate-release layer and sustained-release layer, immediate-release layer can be quickly released, rapidly increase the blood concentration in human body;Sustained-release layer has multi-stage drug release characteristics, it includes three kinds of sustained-release particles, which can effectively delay, positioning release drug, constantly supplement the blood concentration in body, maintain stable blood concentration, can effectively sustain release up to about 12h, and can maintain relatively stable blood concentration within 12 hours, reduce the frequency of drug taking, improve patient compliance, suitable for the patient with herpes simplex virus infection who needs long-term treatment.

The invention relates to an application of polygonum capitatum or an extract of the polygonum capitatum in preparation of an anti-pseudorabies virus drug. The polygonum capitatum is a dry whole herb or an overground part of polygonum capitatum Poly (Polygonum capitatum Buck.-Ham. Ex D.Don) which is a polygonaceae plant. Researches show that the polygonum capitatum extract can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the pseudorabies viruses, the effect of inhibiting the proliferation of the pseudorabies viruses is remarkably superior to that of an antiviral chemical drug acyclovir, and the polygonum capitatum extract can be applied to preparation of the pseudorabies virus resisting medicine. The polygonum capitatum extract is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

This invention provides a traditional Chinese medicine composition for treating herpes zoster, its preparation method, and its application, belonging to the field of traditional Chinese medicine technology. The active ingredients of the traditional Chinese medicine composition include the following two parts: (1) Traditional Chinese medicine active ingredients: by weight, prepared from the following traditional Chinese medicinal materials: 10-15 parts of Isatis root; 10-15 parts of Isatis leaf; 10-15 parts of Astragalus; 8-12 parts of Angelica sinensis; 8-12 parts of white peony root; 6-10 parts of Ligusticum chuanxiong; 5-8 parts of safflower; 5-8 parts of red peony root; 5-8 parts of Salvia miltiorrhiza; 4-7 parts of cicada slough; 4-7 parts of earthworm; 4-7 parts of Saposhnikovia divaricata; and 3-5 parts of licorice; (2) Western medicine active ingredients: composed of acyclovir and famciclovir in a weight ratio of 1:1-3. This invention is a traditional Chinese and Western medicine combined drug developed based on the traditional Chinese medicine treatment of herpes zoster and combined with modern pharmaceutical technology. It adopts bio-enzymatic hydrolysis technology and nano-level drug delivery system, which significantly improves the bioavailability and targeting of the drug. It has a unique therapeutic effect on shingles, and its advanced preparation process results in significant efficacy, short onset time, convenient administration, few adverse reactions, safety and effectiveness. It can also prevent and relieve postherpetic neuralgia, providing a new option for the treatment of shingles.

By utilizing the characteristic that acyclovir cannot corrode normal skin when being externally applied, the acyclovir is mixed with traditional Chinese medicine composite components which are capable of softening cutin, high in permeability, expanding microcirculation and free of ablativity, so that the acyclovir can be applied trustingly, sufficiently, timely, expanded and repeatedly, the effective components of the acyclovir can penetrate into and reside on a basal layer of epidermis for a long time and continuously act on HPV strains, and the treatment effect of the acyclovir is improved. And finally clearing. A large piece of HPV verruca which is lately bred for many years can be removed, and the total treatment effect can reach 90% or above; within a considerable period when no specific medicine exists at present, the ointment can be used as a major ointment for treating the HPV verruca vulgaris (can be matched with an antiviral medicine at the same time).

This invention discloses a compound containing diacylpropidine, its preparation method, and its applications. Remdesivir, acyclovir, vidarabine, and stavudine, along with succinic anhydride, are reacted in dichloromethane to obtain an intermediate containing a monocarboxylic acid; or remdesivir, acyclovir, vidarabine, and stavudine, along with pimelic acid, are condensed in EDC·HCl to obtain an intermediate containing a monocarboxylic acid; a diacylpropidine-containing linker is then condensed with the intermediate containing the monocarboxylic acid in EDC·HCl to obtain a compound containing diacylpropidine. This compound can form covalent bonds with target proteins, achieving irreversible binding, providing a new mechanism of action and binding mode, improving the binding efficacy and duration of action of small molecule inhibitors, and enhancing the intensity and duration of drug action.

The invention discloses a capillary electrochromatography rapid separation and detection method for acyclovir and guanine, and relates to a rapid separation and detection method for acyclovir and guanine. The invention aims to solve the problems of poor separation effect, short service life and poor reproducibility and stability of the conventional chromatographic column on acyclovir and guanine. The method comprises the following steps: 1, preparing a UiO-66-NH2-coated ZIF-8 bonded open tubular column; and 2, separation of acyclovir and guanine. The invention provides a simple, rapid and efficient method for separating and detecting acyclovir and guanine, namely a UiO-66-NH2-ZIF-8 bonded open tubular column with long service life and good reproducibility and stability is obtained through a simple preparation method, a CEC method for separating and detecting acyclovir and guanine is established, and the lowest concentration of guanine which can be detected is 3.6 mu g / mL.

The present invention discloses the use of piperazinone hydroxypyridone compounds in the preparation of anti-herpes simplex virus drugs. Experiments have shown that the piperazinone hydroxypyridone compounds of the present invention can effectively inhibit the replication of herpes simplex virus in Vero cell lines, particularly having an inhibitory effect on acyclovir-resistant herpes simplex virus. The present invention also discloses the antiviral mechanism of the piperazinone hydroxypyridone compounds, which is different from the clinical first-line drug acyclovir. The general structural formula of the piperazinone hydroxypyridone compounds is shown as (I):

The present application relates to the field of antiviral drugs, and particularly relates to application of miRNA mimics in preparation of drugs for resisting type I herpes simplex virus, and provides the miRNA mimics, which is an analogue of miR-H5-5p coded by type I herpes simplex virus, is double-stranded RNA synthesized by a chemical method, has a molecular weight of about 13300 Dalton, and sequences are shown as SEQ ID NO. 1 and SEQ ID NO. 2. The miRNA mimics can show significant activity of resisting type I herpes simplex virus with acyclovir resistance in HEK293T cells and Vero cells, and shows that the miRNA mimics can be used for preparing drugs for resisting type I herpes simplex virus with acyclovir resistance.